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A B S T R A C T   
This work investigated the technical feasibility of preparing, stabilizing and isolating poorly water-soluble drug 
nanoparticles via a small-scale antisolvent precipitation process operating in semi-continuous mode. Specifically, 
a novel semi-continuous process was demonstrated for the carrier particle mediated production, stabilization and 
isolation of valsartan nanoparticles into a solid form using montmorillonite clay particles as the carrier. The semi- 
continuous process operated robustly for the full duration of the experiment (~16 min) and steady-state con-
ditions were reached after ~5 min. Nanoparticles of valsartan (51 ± 1 nm) were successfully prepared, stabilized 
and isolated with the help of montmorillonite (MMT) or protamine functionalized montmorillonite (PA-MMT) 
into the dried form by this semi-continuous route. The dissolution profile of the isolated valsartan nanocomposite 
solids was similar to that of valsartan nanocomposite solids produced via the corresponding laboratory scale 
batch mode process, indicating that the product quality (principally the nanoscale particle size and solid-state 
form) is retained during the semi-continuous processing of the nanoparticles. Furthermore, tablets produced 
via direct compression of the isolated valsartan nanocomposite solids displayed a dissolution profile comparable 
with that of the powdered nanocomposite material. PXRD, DSC, SSNMR and dissolution studies indicate that the 
valsartan nanoparticles produced via this semi-continuous process were amorphous and exhibited shelf-life 
stability equivalent to > 10 months.   
1. Introduction 
Pharmaceutical crystallization is typically carried out in batch re-
actors using cooling, normal and reverse antisolvent addition, evapo-
ration, pH adjustment or chemical reaction to generate supersaturated 
solutions that induce solute molecules to come together to nucleate and 
grow into crystals (Quon et al., 2012; Nagy and Braatz, 2012). However, 
in recent years, there has been increased industrial and academic in-
terest in changing pharmaceutical processing from batch to more effi-
cient continuous processes (Poechlauer et al., 2012; Mascia et al., 2013; 
Wong et al., 2012; Myerson et al., 2014; Tung, 2013; Jiang and Braatz, 
2019). Continuous manufacturing provides several potential opportu-
nities, such as better control of product quality, lower costs, greater 
reliability and safety, better sustainability and increased flexibility (Eder 
et al., 2010; Jiang et al., 2014; Zhang et al., 2012). Although batch 
operation is the more common and well-understood approach, there are 
still significant issues associated with it, such as batch to batch vari-
ability, difficulty in scaling up and producing homogeneous processing 
conditions, which can lead to substantial issues in downstream pro-
cesses, subsequent formulation into medicines and in vivo performance 
(Quon et al., 2012; Zhang et al., 2012; Plumb, 2005; Chen et al., 2011). 
Continuous manufacturing has inherent advantages over batch with 
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respect to process control. The steady-state is usually easier to control 
due to tighter equipment integration as well as a higher level of auto-
mation (Mascia et al., 2013; Lakerveld et al., 2015; Heider et al., 2014; 
Lakerveld et al., 2013; Hadiwinoto et al., 2019). 
Drug nanoparticles at an industrial scale are mainly produced by 
“top-down” techniques such as milling and high-pressure homogeniza-
tion, which basically break down large crystalline drug particles into 
nanoparticles (Keck and Muller, 2006; Dong et al., 2010). In contrast, 
“bottom-up” techniques, which are based on controlled precipitation/ 
crystallization to form nanoparticles by building up particles from the 
molecular state, are rarely used at the industrial scale (Horn and Rieger, 
2001; Rogers et al., 2004). One such bottom-up technique, liquid anti-
solvent precipitation, is a fast, simple and cost-efficient method of 
nanoparticle production. It involves rapidly mixing a solution of drug in 
solvent with a solvent-miscible antisolvent; this generates a high su-
persaturation that induces a fast nucleation rate, leading to the pro-
duction of nanoparticles. However, it has the inherent problem of scale- 
up in batch mode due to the challenge of generating a uniformly high 
supersaturation throughout the large batch volume. The resulting vari-
ation of supersaturation throughout the process volume leads to varia-
tions in precipitation kinetics, which in turn can influence the final 
particle size distribution and quality of the product (Zhang et al., 2012; 
Hadiwinoto et al., 2019). However, performing antisolvent precipitation 
in continuous mode offers the potential to overcome this problem 
because the process can be designed to run using volumes small enough 
to limit the non-uniformity of supersaturation levels. Thus, drug nano-
particle production via continuous antisolvent precipitation not only 
offers the possibility of process intensification but also offers better 
control over particle size distribution relative to batch processing 
(Pandey et al., 2018; D’Addio and Prud’homme, 2011). As such, po-
tential exists to transform current industrial practices by producing drug 
nanoparticles using continuous antisolvent precipitation. 
A thorough search of the pharmaceutical literature for the produc-
tion of drug nanoparticles via antisolvent precipitation shows that the 
majority of experimental data were obtained in batch mode (Thorat and 
Dalvi, 2012; Hu et al., 2011). Very few reports describe the production 
of nanoparticles via continuous antisolvent precipitation, and of these 
the drug nanoparticles were often isolated from suspension into the 
solid-state via coupling the continuous process with spray drying (Dong 
et al., 2010; Horn and Rieger, 2001; Hu et al., 2011; Dong et al., 2014). 
However, isolating nanoparticles into the solid-state using complex 
techniques such as spray drying (and also freeze-drying) can induce 
Fig. 1. A schematic illustration of (a) the semi-continuous preparation of valsartan nanosuspension stabilized by Pluronic® F-127 and (b) the semi-continuous 
preparation, stabilization by MMT/PA-MMT, and isolation of valsartan nanocomposites by filtration. 
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agglomeration of the nanoparticles due to their high surface energy 
(Matteucci et al., 2006; Abdelwahed et al., 2006). 
Our previous work has described a highly effective way to prepare, 
stabilise and isolate nanoparticles of a range of poorly water-soluble 
APIs via a reverse antisolvent precipitation method in batch mode 
(Kumar et al., 2019; Tierney et al., 2017; Tierney et al., 2015; Bodnar 
et al., 2017). Indeed, a good understanding of the batch process is almost 
always required to make a successful design of continuous processes 
(Jiang and Braatz, 2019). The objective of this work was to develop a 
semi-continuous antisolvent precipitation process for preparation, sta-
bilization, and isolation of poorly water-soluble drugs with the help of 
clay carrier particles using an in-house developed semi-continuous sys-
tem. These clay carrier particles served the dual purpose of stabilizing 
the nanoparticles in suspension and allowing for their isolation via 
simple filtration. The process performance was characterized in terms of 
mixing and total residence times. The product quality was characterized 
in terms of the particle size distribution of the nanosuspension, per-
centage isolation, solid-state form, stability of isolated product and 
dissolution rate by comparing them with batch formulations. The model 
compound chosen for this study was valsartan (Val), as it was observed 
in our previous study that Val nanoparticles exhibit good stability when 
precipitated in batch mode with the help of soluble stabilizers or carrier 
particles (Kumar et al., 2019). The aim of this study, therefore, was to 
determine whether Val nanoparticles of similar quality can be prepared, 
stabilized and isolated in a semi-continuous process. Process variables of 
antisolvent precipitation such as antisolvent/solvent ratio, flow rate of 
antisolvent and solvent, residence time and flow rate of suspended 
carrier particles were optimized to control product quality. 
2. Materials and methods 
2.1. Materials 
Valsartan (Val) ((S)-3-methyl-2-(N-{[2′-(2H-1,2,3,4-tetrazol-5-yl) 
biphenyl-4-yl]methyl} pentanamido) butanoic acid) was generously 
supplied by Novartis. Valsartan Form E was prepared from this as- 
received material according to the procedure outlined in the study 
published previously by our group (Kumar et al., 2019). Montmoril-
lonite K10 (MMT), Pluronic® F-127, protamine sulphate salt from 
salmon sperm (PA, a cationic peptide, approx. 5.1 kDa), carboxymethyl 
cellulose (CMC) and methanol (MeOH) were all purchased from Sigma 
Aldrich (Ireland) and were used as received without further purification. 
2.2. Apparatus and experimental procedure for the preparation of 
the valsartan nanosuspensions using Pluronic® F-127 as stabilizer 
in a semi-continuous process 
Fig. 1(a) shows the schematic set up for the semi-continuous pro-
duction of a valsartan nanosuspension via a reverse antisolvent precip-
itation method. The system consists of two magnetic stirrers, a 60 mL 
jacketed vessel maintained at 25 ◦C (precipitation chamber) which was 
initially filled with 60 mL of an aqueous solution of Pluronic® F-127 
(0.2% w/w), a one-liter vessel that contains an aqueous solution of 
Pluronic® F-127 (0.2% w/w), a collection vial, a peristaltic pump, and a 
syringe pump (20 mL) containing the drug solution (100 mg Val/mL 
methanol) in the syringe. During the experiment, the aqueous solution of 
Pluronic® F-127 (antisolvent) and the valsartan solution in methanol 
(solvent) were continuously and simultaneously pumped into the pre-
cipitation chamber at a fixed flow rate of 50 mL/min and 1.13 mL/min, 
respectively, Fig. 1(a). These flow rates were selected to achieve the 
optimum drug solution/anti-solvent ratio in order to obtain the desired 
particle size distribution of valsartan nanoparticles similar to the batch 
process. The working volume of the precipitation chamber was 60 mL, 
which was agitated (800 or 1200 rpm) and overflowed continuously – 
the overflow was collected as discrete aliquots (60 mL) in a series of 
numbered vials, Fig. 1(a). The ‘residence time’ (volume of precipitation 
chamber/total flow rate) of the continuously forming nanosuspension in 
the precipitation chamber was 60 mL/51.13 mL.min− 1 = 1.17 min. The 
overflow aliquots were collected continuously in series every 1.17 min 
such that each aliquot volume represented one nominal complete ‘resi-
dence time’ of the precipitation chamber (i.e. 60 mL). At the defined 
flow rates, the maximum attainable concentration of valsartan in the 
precipitation chamber (assuming complete desupersaturation) was 2.21 
mg/mL. 
2.3. Determination of steady-state for the semi-continuous antisolvent 
precipitation process 
The time required to achieve steady-state conditions for the semi- 
continuous antisolvent precipitation process was defined as the time 
required to reach the maximum attainable concentration of valsartan (i. 
e. 2.21 mg/mL) in the precipitation chamber at the defined flow rates of 
solvent (drug solution) and antisolvent (aqueous solution of Pluronic® 
F-127). This was determined by analyzing the concentration of valsartan 
in each aliquot volume (mg/mL) using a Shimadzu UV-1800 UV–Visible 
spectrophotometer (λ = 250 nm) after firstly diluting the aliquot volume 
40-fold in methanol. The process was deemed to have reached steady 
state once the valsartan concentration had reached its maximum 
attainable value (2.21 mg/mL in the precipitation chamber mixture) and 
thereafter remained at this constant value, from one aliquot to the next. 
2.4. Particle Sizing 
The particle size distribution of the Pluronic® F-127 stabilized val-
sartan nanosuspension produced via the semi-continuous antisolvent 
precipitation process was determined using a Malvern Zetasizer Nano 
ZSP system with water as the dispersion medium. A refractive index of 
1.55 and an absorption index of 0.1 were used to measure the particle 
size distribution of the valsartan nanoparticles. Each sample was 
equilibrated for 120 s at 25 ◦C prior to the measurement. Ten sub- 
measurements were taken per run and each sample was run in tripli-
cate. The average D50 diameter and the standard deviation were recor-
ded for each sample. 
The particle size distributions of bare MMT, the Val-MMT nano-
composite suspension and the dried Val-MMT nanocomposite powder 
were determined by laser diffraction using a Malvern Mastersizer 3000, 
with water as the dispersion medium. An obscuration rate of 7–9%, a stir 
speed of 2000 rpm, and pre-measurement delay of 30 s were used for 
each measurement. A refractive index of 1.55 and an absorption index of 
Fig. 2. The concentration of valsartan (mg/mL) in each of the aliquots 
collected in series. Each aliquot volume corresponds to one residence time of 
the precipitation chamber (i.e. 60 mL), and the maximum attainable concen-
tration of valsartan is 2.21 mg/mL based on the flow rates of the solvent 
(valsartan solution) and antisolvent (aqueous solution of Pluronic® F-127). 
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0.1 were used to measure the particle size distribution of the bare MMT 
and the Val-MMT nanocomposites. Three measurements were taken per 
run and each sample was run in triplicate. The average D50 diameter and 
the standard deviation were recorded for each sample. 
2.5. Apparatus and experimental procedure for the preparation of 
valsartan-montmorillonite (Val-MMT) and valsartan-protamine 
functionalised montmorillonite (Val-PA-MMT) nanocomposites via semi- 
continuous antisolvent precipitation 
The production of Val-MMT and Val-PA-MMT nanocomposites (NCs) 
via semi-continuous antisolvent precipitation was achieved as per the 
process described in Section 2.2 except that the solution of Pluronic® F- 
127was replaced by (i) aqueous suspensions of MMT of different con-
centrations (5 mg/mL to 25 mg/L) agitated at 800 rpm, or (ii) an MMT 
suspension (5 mg/mL) in an aqueous solution of PA (3 mg PA/g of MMT) 
agitated at 800 rpm; PA, which is a cationic peptide, was used in our 
previous study to limit the aggregation of valsartan nanoparticles on 
MMT carrier particles at high valsartan loadings (Kumar et al., 2019). 
The collection vial was replaced by a simple Buchner filtration set-up to 
isolate the Val-MMT or Val-PA-MMT nanocomposites produced at 60 mL 
aliquot intervals as shown in Fig. 1(b). The isolated nanocomposite 
materials were dried in a fume hood at ambient temperature and pres-
sure for 24 h. The percentage of Val nanoparticles adsorbed onto the 
MMT/PA-MMT carrier particles was determined (indirectly) by 
measuring the concentration of valsartan in the filtrate (i.e. the unad-
sorbed valsartan) on a Shimadzu UV-1800 spectrophotometer (λ = 250 
nm) by taking an aliquot of the filtrate and diluted by a factor of 10 in 
methanol to dissolve any drug particles present in the filtrate prior to the 
measurement. For comparison purpose, Val-MMT/Val-PA-MMT NCs at 
different valsartan loadings (% w/w) were also prepared in a batch 
experiment according to the procedure outlined in the study published 
previously by our group (Kumar et al., 2019). 
2.6. Powder X-ray diffraction (PXRD) 
Reflection powder X-ray diffractograms (PXRDs) were recorded 
using an Empyrean diffractometer (PANalytical, Phillips) with Cu Kα1,2 
radiation (λ = 1.5406 Å) operating at 40 kV and 40 mA at room tem-
perature. Samples were scanned from 5 to 50◦ (2θ) with 0.026◦ 2θ/min 
step size and 112.97 s per step, on a flat stage that was spinning at 4 rpm. 
2.7. Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was carried out using a 
PerkinElmer instrument Pyris 1 DSC in the range 30–170 ◦C at a scan 
rate of 10 ◦C/min under a nitrogen environment (30 mL/min). Experi-
ments were carried out using platinum pans with pinholes (as manu-
factured), sealed by a crimping press. The instrument was calibrated 
using samples of indium and lead. 
2.8. Solid-state nuclear magnetic resonance (SSNMR) 
13C SSNMR cross-polarization magic-angle spinning (CPMAS) 
spectra were collected with a Bruker Avance III HD NMR spectrometer, 
operating at 400.23 and 100.63 MHz, for 1H and 13C respectively. Dry 
powdered samples were packed without further preparation into cylin-
drical zirconia rotors with a 4 mm o.d. and an 80 μL volume. The 13C 
CPMAS spectra were acquired at room temperature at a spinning speed 
of 12 kHz, using a ramp cross-polarization pulse sequence with a 90◦ 1H 
pulse of 3 μs, a contact time of 3 ms, an optimized recycle delay of 3.14 s 
and a number of scans included in the range 400–26900, depending on 
the sample. A two-pulse phase modulation (TPPM) decoupling scheme 
was used, with a radiofrequency field of 69.4 kHz. The 13C chemical shift 
scale was calibrated through the low field peak signal of an external 
standard, adamantane (at 38.48 ppm). 
2.9. Tableting 
The greater productivity of the semi-continuous method (compared 
with the batch method) allowed a small number of tablets to be 
formulated and tabletted. Dried Val-MMT/Val-PA-MMT nanocomposite 
solids with various Val loadings (% w/w) were tabletted with a 
compaction simulator (Gamlen Tableting D series) using a 6 mm round 
and flat-faced punch and die set. Two formulations were made; the first 
Fig. 3. Particle size distributions of valsartan nanosuspensions at steady state 
(i.e. after the 4th residence time) following reverse antisolvent precipitation in 
semi-continuous mode in the presence of Pluronic® F-127 at stirring speeds of 
800 and 1200 rpm. 
Fig. 4. Particle size distribution of bare and valsartan loaded MMT before and 
after filtering and drying. 
Fig. 5. Tensile strength of bare MMT and Val-MMT/Val-PA-MMT NCs tablets at 
different valsartan loadings (% w/w) compressed at a load of 300 kg, n = 3. 
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formulation contains only Val-MMT/Val-PA-MMT NCs while the second 
formulation comprised a blend of Val-MMT/Val-PA-MMT NCs and CMC 
(10% w/w) as disintegrant. For each compression, 100 mg of sample 
(100 mg Val-MMT/Val-PA-MMT NCs or 100 mg sample containing 90% 
w/w Val-MMT/Val-PA-MMT NCs and 10% w/w CMC as disintegrant) 
was manually filled into the die and compacted by applying loads of 160 
to 300 kg at a controlled upper punch velocity of 1 mm s− 1. Load 
displacement data were used to calculate detachment and ejection 
stresses using in-die Heckle analysis. The tablet crushing force, hardness 
(F), thickness (h), diameter (D), and weight of the tablets produced were 
determined using a PTB 311E pharm test hardness tester. The tablet 




πDh (1)  
where F = hardness (N), h = tablet thickness (mm) and D = tablet 
diameter (mm). 
Fig. 6. Tensile strength of Val-MMT NC tablets at 8.2% and 18% w/w valsartan 
loadings and Val-PA-MMT NC tablets at 30% w/w valsartan loading (3 mg PA/g 
MMT), compacted at loads of 300, 200 and 160 kg respectively, n = 3. 
Fig. 7. Comparison of the dissolution profile of Val Form E (~11 µm) with those of dried Val-MMT nanocomposite powders prepared in the batch experiment and 
dried Val-MMT nanocomposite powders prepared in the semi-continuous experiment at different valsartan loadings: (a) 9% w/w loading, (b) 20% w/w loading, (c) 
33.3% w/w loading and (d) 33.3% loading, 3 mg PA/g MMT. 
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Tensile strength in excess of 1 MPa is usually desirable for tablets 
(Schmidtke et al., 2017). 
2.10. In vitro drug release studies 
In vitro drug release studies of (i) valsartan Form E and (ii) dried 
powders of Val-MMT/Val-PA-MMT NCs at different valsartan loadings 
ranging from 9 to 33.3% w/w were carried out in sink conditions in 100 
mL deionized water under continuous agitation (300 rpm) at 37 ± 0.5 
◦C. The extent of drug dissolution was measured using a Shimadzu UV- 
1800 UV–Visible spectrophotometer at λ = 250 nm by withdrawing 1 
mL aliquots at pre-determined time intervals (0.5, 1.5, 3, 5, 10, 15, 30, 
45 and 60 min) from the bulk solution with a preheated plastic syringe 
and filtering through 0.22 µm pore preheated PTFE syringe filters. All 
measurements were carried out in triplicate. 
In vitro drug release studies of the tablet formulation of Val-MMT/ 
Val-PA-MMT NCs and powdered formulation composed of a physical 
mix of Val-MMT/Val-PA-MMT NCs and CMC were carried out using a 
USP compliant tablet dissolution type II (Pharma Test PTWS 120D) 
paddle apparatus. They were carried out in sink conditions in 900 mL 
deionized water at 37 ± 0.5 ◦C at a paddle rotation of 150 rpm. One mL 
aliquots were withdrawn at predetermined time intervals and the 
amount of valsartan released was determined via UV-1800 UV–Visible 
spectrophotometer as described above. All measurements were carried 
out in triplicate. 
2.11. Accelerated stability tests 
To investigate the stability of the nanocomposites over time, samples 
of Val-MMT and Val-PA-MMT NCs (all in dry solid form) were exposed 
to 40 ◦C and 75% relative humidity for 2.5 months in a closed desiccator 
containing a supersaturated solution of NaCl. After 2.5 months, the 
samples were analysed via DSC, PXRD and SSNMR, and in vitro drug 
release studies were also performed, to determine whether the material 
had changed through recrystallization or agglomeration. 
Fig. 8. Comparison of the dissolution profile of fresh dried Val-MMT nanocomposites prepared in the semi-continuous experiment with those of aged Val-MMT 
nanocomposites prepared in the semi-continuous experiment (samples stored for 2.5 months in an accelerated humidity chamber at 40 ◦C and 75% relative hu-
midity) at different valsartan loadings: (a) 9% w/w loading, (b) 20% w/w loading, (c) 33.3% w/w loading and (d) 33.3% loading, 3 mg of PA/g MMT. 
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3. Results and discussion 
3.1. Steady-state measurement 
At the studied flow-rates, one nominal complete ‘residence time’ of 
the precipitation chamber (i.e. 60 mL) took 1.17 min to collect as a 
discrete aliquot, as discussed in Section 2.2. Also, the maximum 
attainable concentration of valsartan in the precipitation chamber was 
2.21 mg/mL. As such, steady state conditions were deemed achieved 
once the valsartan concentration had reached 2.21 mg/mL in the pre-
cipitation chamber mixture and thereafter remained at this constant 
value from one discrete collected aliquot to the next. On this basis, the 
system was found to achieve steady state operation after four ‘residence 
times’, which equated to the collection of four aliquots over ca. 5 min (4 
residence times × 1.17 min/residence time). Thereafter the semi- 
continuous system operated robustly for the entire duration of the 
experiment (~16 min), Fig. 2. At these flow rates, ~3 L of 
nanosuspension can be produced per hour, and while the single- 
injection system used here limited the duration of the experiment, a 
parallel syringe injection system would allow for longer running times. 
3.2. Particle size distribution of polymer stabilized nanosuspensions from 
the semi-continuous preparation 
Rapid mixing during antisolvent precipitation is necessary to 
generate small particles and narrow particle size distributions (Thorat 
and Dalvi, 2012). The steady-state particle size distribution of valsartan 
nanoparticles stabilized by Pluronic® F127 changes from 68 ± 7 nm to 
51 ± 1 nm as the stirring speed increased from 800 to 1200 rpm in the 
precipitation chamber, Fig. 3. Thus rapid mixing appears to generate a 
more homogeneous solution, with a uniformly high supersaturation, 
which results in faster nucleation rates generating smaller particle sizes. 
The particle size distribution at 800 rpm was not as narrow as that ob-
tained during the batch experiment in which the particle size of 50 ± 0.4 
Fig. 9. Comparison of the dissolution profile of Val Form E (~11 µm) with those for valsartan from a selection of powdered samples and tablet formulations at 
different valsartan loadings (% w/w) and where the formulations comprised a 90:10 w/w blend of Val-MMT or Val-PA-MMT NCs and CMC as disintegrant: (a) 
powdered sample composed of a physical mix of Val-MMT NCs and CMC (Val loading = 8.2% w/w), and Val-MMT NCs tablet (Val loading = 8.2% w/w, tensile 
strength = 1.1 MPa), (b) powdered sample composed of a physical mix of Val-MMT NCs and CMC (Val loading = 18% w/w), and Val-MMT NCs tablet (Val loading =
18% w/w, tensile strength = 2 MPa), and (c) powdered sample composed of a physical mix of Val-PA-MMT NCs and CMC (Val loading = 30% w/w, 3 mg PA/g 
MMT), and Val-PA-MMT NCs tablet (Val loading = 30% w/w, 3 mg PA/g MMT, tensile strength = 2.6 MPa); n = 3. 
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nm was obtained with very narrow particle size distribution at 800 rpm 
(Kumar et al., 2019). However, when the stirring was increased to 1200 
rpm, the particle size distribution obtained during the semi-continuous 
process was similar to the batch particle size distribution at 800 rpm, 
Fig. 3. This can be attributed to the different level of mixing that is 
required when comparing the batch experiment with the semi- 
continuous. All subsequent semi-continuous studies were therefore 
conducted at the optimized stirring speed of 1200 rpm. 
3.3. Attachment of valsartan nanoparticles onto MMT/PA-MMT carrier 
particles during the semi-continuous process 
In our previous study, almost complete adsorption (>99%) of val-
sartan nanoparticles onto MMT or PA-MMT carrier particles was 
observed using the batch process (Kumar et al., 2019). The attachment 
of Val nanoparticles to MMT/PA-MMMT carrier particles during the 
semi-continuous process was confirmed by the clear filtrate obtained in 
each aliquot and by checking the concentration of valsartan in the 
filtrate by UV–Vis analysis. The concentration of valsartan in the filtrate 
confirmed that almost all of the valsartan present had adsorbed onto the 
MMT/PA-MMT carrier particles (>99%). Thus it can be said that this 
semi-continuous system is successful in preparing and isolating drug 
nanoparticles in the solid-state in which > 99% of the drug nano-
particles are adsorbed onto the carrier particles. 
The particle size distributions of the bare MMT, 9.09% w/w valsar-
tan loaded Val-MMT nanocomposites suspension, 9.09% w/w dried 
valsartan loaded Val-MMT nanocomposites and 33.3% w/w dried val-
sartan loaded Val-MMT nanocomposites were found to be the same (at 
26.0 ± 0.5, 26.3 ± 0.4, 25.5 ± 1.5 and 26 ± 2 µm respectively, Fig. 4). 
Fig. 10. Comparison of the dissolution profile of Val Form E (~11 µm) with those for valsartan from a selection of powdered samples and tablet formulations at 
different valsartan loadings (% w/w) and where the formulations comprised a 90:10 w/w blend of Val-MMT or Val-PA-MMT NCs and CMC as disintegrant: (a) 
powdered sample composed of a physical mix of Val-MMT NCs and CMC (Val loading = 8.2% w/w), and Val-MMT NCs tablet (Val loading = 8.2% w/w, tensile 
strength = ~1 MPa), (b) powdered sample composed of a physical mix of Val-MMT NCs and CMC (Val loading = 18% w/w), and Val-MMT NCs tablet (Val loading =
18% w/w, tensile strength = ~1 MPa), and (c) powdered sample composed of a physical mix of Val-PA-MMT NCs and CMC (Val loading = 30% w/w, 3 mg PA/g 
MMT), and Val-PA-MMT NCs tablet (Val loading = 30% w/w, 3 mg PA/g MMT, tensile strength = ~1 MPa); n = 3. 
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3.4. Tableting of Val-MMT nanocomposites 
Solid Val-MMT NC products obtained from semi-continuous experi-
ments were compressed to assess the tableting behaviour of Val-MMT/ 
Val-PA-MMT NCs at various Val loadings (% w/w). These tablets’ ten-
sile strength was observed to increase with an increase in valsartan 
loading in the Val-MMT NCs Fig. 5. This was probably due to an increase 
in cohesive interparticulate forces (such as mechanical interlocking, Van 
der Waals forces, etc.) arising from an increase in the nanoparticle 
surface area available for contact and cohesion during tableting at 
higher loadings of valsartan nanoparticles (Eichie and Kudehinbu, 2009; 
Cabiscol et al., 2020; Virtanen et al., 2010). A tensile strength in excess 
of 1 MPa is usually desirable for tablets (Schmidtke et al., 2017). The 
tensile strength of all the tablets with different valsartan loadings 
exceeded this limit, thus yielding robust tablets without any use of other 
excipients, Fig. 5 (Schmidtke et al., 2017; Pitt and Heasley, 2013). While 
this finding is specific to valsartan, it demonstrates the potential of 
nanocomposites produced via this semi-continuous approach to be 
directly compressed into tablets without the need to use other excipi-
ents. The tablets produced were composed only of the nanocomposite 
material and 10% w/w disintegrant (CMC). Thus, the drug loading in the 
tablets was slightly below that of the drug loading in the nanocomposite 
materials; for example, 33.3% w/w/ drug loaded nanocomposite yiel-
ded tablets with a 30% w/w drug loading. The tensile strength of Val- 
MMT/Val-PA-MMT NC tablets at different valsartan loadings was kept 
similar by compressing the 9% and 20% w/w loaded Val-MMT NCs and 
the 33.3% w/w loaded Val-PA-MMT NC (3 mg PA/g MMT) tablets at 
compression loads of 300, 200 and 160 kg respectively Fig. 6. 
3.5. Dissolution studies of Val-MMT nanocomposites powders produced 
via the semi-continuous method 
Fig. 7 shows the dissolution behaviour of Val-MMT NC powders with 
9%, 20% and 33.3% w/w valsartan loadings and Val-PA-MMT NC 
Freshly prepared 





Fig. 11. PXRD patterns of valsartan Form E (experimental and from the CSD), a 33.3% w/w physical mixture of valsartan Form E and MMT, MMT and a selection of 
Val-MMT nanocomposites with different valsartan loadings (% w/w) produced via the semi-continuous method: (a) freshly prepared Val-MMT nanocomposites and 
(b) aged Val-MMT nanocomposites (2.5 months’ storage under accelerated humidity conditions). 
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powder at 33.3% w/w valsartan loading (3 mg PA/g of MMT). For 
comparison purposes, this figure also includes the dissolution of Val- 
MMT NCs at different valsartan loading (w/w) (9%, 20%, 33.3% and 
33.3% loading, 3 mg PA/g of MMT) prepared in a batch experiment and 
Val Form E powder. The dissolution behaviour of Val-MMT nano-
composites produced in the semi-continuous method was found to be 
comparable with those prepared in the batch experiments, and they 
dissolved much faster than the larger particle sized crystals of Val Form 
E (~11 µm), Fig. 7. Thus the semi-continuous method of preparing, 
stabilizing and isolating valsartan nanoparticles is on a par with the 
batch method in terms of dissolution behaviour. 
3.6. Stability of Val-MMT/Val-PA-MMT nanocomposites powders 
After storage for 2.5 months under accelerated humidity conditions, 
Val-MMT and Val-PA-MMT nanocomposites displayed valsartan disso-
lution profiles comparable with those of freshly prepared Val-MMT and 
Val-PA-MMT nanocomposites, Fig. 8. This indicates that no recrystalli-
zation/polymorphic transformation/aggregation of the valsartan 
nanoparticles had occurred during this time. Thus, the Val-MMT/Val- 
PA-MMT nanocomposites produced via this semi-continuous process 
possessed a shelf-life stability equivalent to > 10 months (based on the 
accelerated stability storage conditions of 40 ◦C and 75% relative hu-
midity for 2.5 months), Fig. 8. 
3.7. Dissolution studies of Val-MMT nanocomposites tablets 
The tablet (100 mg) formulation used for dissolution studies 
comprised a 90:10 w/w blend of Val-MMT or Val-PA-MMT NCs and 
CMC as disintegrant. The dissolution profiles of valsartan from tablets at 
different valsartan loadings are presented in Figs. 9 and 10; the stated 
valsartan loadings take into account the presence of 10% (w/w) CMC in 
the formulation. The dissolution profile of valsartan from the tablets was 
found to deteriorate as the valsartan loading in the tablets increased 
(Fig. 9). This appears to correlate with the increase in tensile strength of 
the tablets as the valsartan loading increases (discussed in Section 3.4). 
To minimise the effect of the tablets’ varying tensile strength on disso-
lution behaviour, 90:10 w/w blends of Val-MMT or Val-PA-MMT NCs 
Fig. 12. DSC thermograms of valsartan Form E, a 33.3% w/w physical mixture of valsartan Form E and MMT, MMT and a selection of Val-MMT nanocomposites with 
different valsartan loadings (% w/w): (a) freshly prepared Val-MMT nanocomposites and (b) aged Val-MMT nanocomposites (2.5 months’ storage under accelerated 
humidity conditions). 
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and CMC at different valsartan loadings were compressed to different 
compression loads in order to form tablets of a similar tensile strength 
(~1 MPa) for dissolution studies (discussed in Section 3.4). The disso-
lution profiles of valsartan from the resulting tablet formulations were 
comparable with those of the corresponding powdered physical mix 
samples of Val-MMT NCs and CMC as illustrated in Fig. 10. Hence, the 
tableting of Val-MMT nanocomposites powder does not adversely affect 
the dissolution profile once the tablet compression load has been tuned 
accordingly to control the tensile strength. In principle, therefore, API- 
MMT nanocomposites obtained from this semi-continuous process can 
be readily compressed into tablets without compromising the dissolu-
tion behaviour of the APIs. 
3.8. Solid state characterization 
PXRD patterns were compared for Val Form E, a 33.3% w/w physical 
mixture of Val Form E and MMT, MMT, and variously valsartan-loaded 
Val-MMT NCs produced via the semi-continuous process (freshly pre-
pared samples (Fig. 11(a)) and samples following 2.5 months’ storage 
under accelerated humidity conditions (Fig. 11(b))). No characteristic 
valsartan diffraction peaks were observed in any of the variously 
valsartan-loaded Val-MMT nanocomposites, thus confirming the X-ray 
amorphous nature of the valsartan in the fresh samples and the samples 
stored for 2.5 months under accelerated humidity conditions. DSC 
thermograms were compared for Val Form E, a 33.3% w/w physical 
mixture of Val Form E and MMT, MMT, and variously valsartan-loaded 
Val-MMT NCs produced via the semi-continuous process (freshly pre-
pared samples (Fig. 12(a)) and samples following 2.5 months’ storage 
under accelerated humidity conditions (Fig. 12(b))) to further investi-
gate the physical state of valsartan in the Val-MMT nanocomposites. The 
thermogram of unprocessed Val Form E showed an endothermic peak at 
138.4 ± 0.4 ◦C corresponding to its melting temperature, as did the 
thermogram of its 33.3% w/w physical mixture with MMT. However, a 
melting peak was not detected in any of the thermograms of the vari-
ously valsartan-loaded Val-MMT nanocomposite samples, suggesting 
that the adsorbed valsartan nanoparticles therein were amorphous when 
freshly produced and did not undergo a crystalline transformation 
during 2.5 months’ storage under accelerated humidity conditions, 
Fig. 12(a) and (b). 
3.9. Solid-state nuclear magnetic resonance (SSNMR) of Val-MMT 
nanocomposites 
Solid-state NMR (SSNMR) has established itself as a complementary 
technique to X-ray diffraction in the study of solid materials, especially 
in the case of APIs (Chierotti and Gobetto, 2008; Bordignon et al., 2017; 
Rossi et al., 2018; Geppi et al., 2008; Veinberg et al., 2016). Indeed, 
contrary to solution NMR, SSNMR does not require the dissolution of the 
sample to be analyzed, thus avoiding the loss of any feature intimately 
connected with its structure in the solid-state. It can provide precious 
information about poorly crystalline or even amorphous samples (Lu 
et al., 2019; Agrawal et al., 2004). Moreover, thanks to its high sensi-
tivity to the local environment of the observed nuclei, SSNMR can be 
employed to probe the effects of surface interactions on the materials of 
interest (Vogt et al., 2013; Paudel et al., 2014). 13C cross-polarization 
magic-angle spinning (CPMAS) spectra were acquired for crystalline 
Val Form E, freshly prepared Val-MMT NCs with different valsartan 
loadings (16.6%, 20% and 33% w/w) and aged Val-MMT NCs (20% and 
33% w/w loading) following 2.5 months’ storage under accelerated 
humidity conditions. This allowed the physical state of the valsartan in 
freshly prepared and aged Val-MMT nanocomposites to be evaluated. 
Fig. 13 shows the 13C CPMAS spectra of Val Form E and the freshly 
prepared Val-MMT NCs. 
When compared with the signals in the spectrum for crystalline Val 
Form E, the signals in the spectra for the three Val-MMT nanocomposites 
are consistent with the presence of Val. The resonances in the three Val- 
MMT NCs spectra are consistently broader than those for crystalline Val 
Form E, with an average full width at half maximum value of about 350 
Hz for the Val-MMT NCs spectra versus about 90 Hz for Val Form E. This 
is due to a loss of crystallinity of valsartan in the Val-MMT NCs, sug-
gesting that the adsorbed valsartan nanoparticles thereon are amor-
phous. This was confirmed by comparing the spectra for the Val-MMT 
nanocomposites with that for amorphous valsartan reported by Skot-
nicki et al. in 2016 (Skotnicki et al., 2016) (not shown). The spectra of 
the three freshly prepared Val-MMT NCs at different Val loadings in 
Fig. 13 are superimposable on each other, indicating that the valsartan is 
not meaningfully affected by different interactions in the three materials 
as its loading on MMT varies. Above the spectra in Fig. 13, valsartan’s 
chemical structure is shown, with C atoms numbered to clarify the 
Fig. 13. 13C (100 MHz) CPMAS spectra of Val Form E and freshly prepared Val- 
MMT NCs (16.6%, 20% and 33% w/w loadings), acquired at a spinning speed 
of 12 kHz at room temperature. 
Fig. 14. 13C (100 MHz) CPMAS spectra of aged Val-MMT NCs (20% and 33% 
w/w loadings) after 2.5 months’ storage under accelerated humidity conditions 
and freshly prepared Val-MMT NC (33% w/w loading), acquired at a spinning 
speed of 12 kHz at room temperature. 
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proposed assignments of the related 13C solid-state NMR resonances. 
Fig. 14 represents a stack of the 13C CPMAS spectra for the two aged Val- 
MMT NC samples (samples were stored for 2.5 months in the accelerated 
testing humidity chamber) and the freshly prepared 33% w/w loaded 
Val-MMT NC sample. As in the previous figure, the three spectra are 
superimposable, suggesting that the 2.5 months’ storage under accel-
erated humidity conditions does not alter the physical state of valsartan 
in the Val-MMT nanocomposites. This confirms the excellent humidity 
stability of Val-MMT nanocomposites with an ambient shelf life of > 10 
months (based on the accelerated stability storage conditions of 40 ◦C 
and 75% relative humidity for 2.5 months). 
4. Conclusion 
An experimental study was conducted to develop a semi-continuous 
and scalable process to prepare, stabilize and isolate valsartan (Val) 
nanoparticles. The reverse anti-solvent precipitation method combined 
with the capture and stabilization of the Val nanoparticles by mont-
morillonite (MMT) or protamine (PA) functionalised MMT lends itself 
readily to semi-continuous operation whereby gram scale quantities of 
Val-MMT/Val-PA-MMT nanocomposites are readily produced at a 
nominal reactor scale of 60 mL. The in-house developed semi- 
continuous system operated robustly for the full duration of all experi-
ments (~16 min) and steady-state conditions were reached within ~ 5 
min. The dissolution profiles of the resulting Val-MMT/Val-PA-MMT 
nanocomposite powders were comparable with those of the corre-
sponding Val-MMT/Val-PA-MMT nanocomposite powders produced via 
batch processing. Furthermore, the dissolution profiles of tablets 
formulated from a 90:10 w/w blend of the Val-MMT/Val-PA-MMT 
nanocomposite powders with CMC (as a disintegrant) were compara-
ble with those of the corresponding physical mixtures up to the highest 
tested valsartan loading of 33.3% w/w, once the tablet compression 
loads had been tuned accordingly to control the tensile strength. Ac-
cording to PXRD, DSC and SSNMR data, the Val-MMT nanocomposites 
were amorphous and have a shelf life stability equivalent to > 10 
months (based on their observed stability up to 2.5 months under 
accelerated testing conditions of 40 ◦C and 75% relative humidity). 
Thus, the developed semi-continuous process in this study offers a rapid 
and robust template for preparing stable API nanosuspensions, which 
can then be readily isolated via adsorption (at different API loadings) 
onto inert carrier particles. The resulting API-carrier particle nano-
composite solids are suitable for tableting, affording fast-dissolving 
tablets for oral dosage forms. 
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